Factors Associated to Success of Hepatitis C Therapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00514111|
Recruitment Status : Completed
First Posted : August 9, 2007
Last Update Posted : March 20, 2009
|Condition or disease||Intervention/treatment|
|Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted||Drug: pegylated-interferon, conventional-interferon, ribavirin|
|Study Type :||Observational|
|Actual Enrollment :||100 participants|
|Official Title:||Factors Associated to Success of Hepatitis C Therapy|
|Study Start Date :||August 2007|
|Actual Primary Completion Date :||July 2008|
|Actual Study Completion Date :||December 2008|
HVC patients attended in SAE e HD.
Drug: pegylated-interferon, conventional-interferon, ribavirin
Genotype 1: pegylated-interferon 2a or 2b plus ribavirin for 48 weeks. Genotype 3: conventional-interferon 2a or 2b plus ribavirin for 24 weeks.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00514111
|SAE e Hospital Dia de Aids|
|Botucatu, Sao Paulo, Brazil, 18618970|
|Principal Investigator:||Alexandre N Barbosa, MD, MSc||UPECLIN HC FM Botucatu Unesp|